Results of survival time analyses in patients undergoing TAVI (multiple Cox regression analysis)
| Tested variables | Crude HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value (Cox) |
| NTproBNP >4970.5 | 1.71 (1.0 to 2.8) | 0.037 | ns | |
| OPN >990.5 | 2.15 (1.31 to 3.53) | 0.002 | 2.06 (1.2 to 3.5) | 0.005 |
| Log ES >20% | 2.41 (1.5 to 4.0) | 0.001 | 2.09 (1.24 to 3.51) | 0.005 |
| ES II >10.3% | 1.89 (1.1 to 3.2) | 0.018 | ns | |
| STS PROM score >20% | 2.03 (1.1 to 3.7) | 0.019 | ns | |
| AFIB/AFLUT | 1.80 (1.1 to 3.0) | 0.020 | 1.71 (1.04 to 2.83) | 0.046 |
| COPD | 1.99 (1.2 to 3.4) | 0.011 | 1.77 (1.04 to 3.04) | 0.036 |
| TA access* | 1.59 (1.0 to 2.7) | 0.075 | 2.01 (1.12 to 3.42) | 0.011 |
| TAo access* | 2.43 (1.1 to 5.6) | 0.038 | 2.19 (0.94 to 5.11) | 0.071 |
*Compared with transfemoral.
AFIB, atrial fibrillation; AFLUT, atrial flutter; COPD, chronic obstructive pulmonary disease; ES II, EuroSCORE II; Log ES, logistic EuroSCORE; ns, non-significant; NTproBNP, N-terminal probrain natriuretic peptide; OPN, osteopontin; STS, Society of Thoracic Surgeons; TA, transapical; Tao, transaortic; TAVI, transcatheter aortic valve implantation.